|Bid||1.4200 x 4600|
|Ask||1.4400 x 100|
|Day's Range||1.4216 - 1.4385|
|52 Week Range||1.2700 - 15.5000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.30|
If you are looking to invest in Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
CHARLOTTESVILLE, Va., Nov. 20, 2017-- Diffusion Pharmaceuticals Inc., is a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule ...
On November 13, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the third quarter of 2017. As expected, the company did not report any revenues. Diffusion reported net income of $5.1 million, or $0.37 per share, which was the result of a non-cash gain of $8.4 million related to the change in the fair value of warrant liabilities due to a decrease in the fair market value of the company’s common stock and not indicative of ongoing operations.
FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial“ First Patient In” Expected this Year Company Charter Amendment Addresses Nasdaq Listing Issue Additions to Board and Management ...
NEW YORK, NY / ACCESSWIRE / October 18, 2017 / Shares of Neothetics and Diffusion Pharmaceuticals saw big gains in Tuesday trading after the companies had positive news respectively. Neothetics soared ...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 35% upturn. The US drug discovery and development firm announced that it has received final protocol guidance from the FDA for a Phase 3 clinical trial with the Company’s lead compound trans sodium crocetinate (TSC) in patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer. The Company has responded to all outstanding points raised by the FDA and plans to begin the trial under the protocol agreed to by the FDA by the end of 2017.
CHARLOTTESVILLE, Va., Oct. 10, 2017-- Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related ...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Diffusion Pharmaceuticals Is DFFN still cheap? Great news forRead More...
Diffusion (DFFN) is a biopharmaceutical company focused on the development of treatments that augment the effects seen from current standard of care cancer therapies. The company’s lead compound is trans sodium crocetinate (TSC), a small molecule that improves the diffusion of oxygen through the bloodstream in order to increase tissue oxygenation. This increase in oxygenation results in increased efficacy for radiation and chemotherapeutic cancer treatments, particularly for those that target hypoxic tumors such as glioblastoma multiforme (GBM) and pancreatic cancer.
NEW YORK, NY / ACCESSWIRE / July 21, 2017 / U.S. markets were mixed Thursday as a sharp drop in Home Depot shares dragged down the Dow Jones and S&P 500 Index, while the Nasdaq continued to climb to new ...
LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on improving the results of cancer treatments such as radiation ...
On May 15, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the first quarter of 2017. As expected, the company did not report any revenues. The decrease was due to decreased expenses attributable to the pancreatic cancer program and animal toxicology.
On March 31, 2017, Diffusion (DFFN) announced financial results for the fourth quarter and full year for 2016. For the full year, Diffusion had a net loss of $18.0 million, or $1.76 per share, which was comprised of $7.3 million in R&D expenses and $11.0 million in G&A expenses compared to $3.9 million in R&D expenses and $2.5 million in G&A expenses for 2015. In April 2017, Diffusion announced the closing of an oversubscribed private placement that raised gross proceeds of $25.0 million from the sale of approximately 12.4 million shares of Series A Convertible Preferred Stock for $2.02 per share.
NEW YORK, NY / ACCESSWIRE / March 29, 2017 / These two companies, one involved in cancer drug research, the other in cholesterol testing devices, both saw their stocks rise as investors heard of their ...
Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.